Sonire Therapeutics
Stub active Updated Apr 15, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Investors
Founders
About
Sonire Therapeutics is a clinical-stage medical device company pioneering next-generation HIFU (High-Intensity Focused Ultrasound) therapy for non-invasive cancer treatment, beginning with pancreatic cancer 1. Founded in Tokyo in February 2020, the company is now headquartered in Palo Alto, California 1. Sonire received FDA Breakthrough Device Designation in 2024 for its HIFU pancreatic cancer ablation system 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-04-15 | Series A | $18M | Sante Ventures | Fast Track Initiative, Nomura SPARX Investment, SBI Investment 1 |
What Investors Say
No verified investor quotes available at this time.
What Founders Say
No verified founder quotes available at this time.
Sources
-
PRNewsWire, “Sonire Therapeutics Closes $18 Million Series A Financing to Advance Breakthrough HIFU Therapy for Pancreatic Cancer, Expands U.S. Clinical Development,” April 15, 2026. https://www.prnewswire.com/news-releases/sonire-therapeutics-closes-18-million-series-a-financing-to-advance-breakthrough-hifu-therapy-for-pancreatic-cancer-expands-us-clinical-development-302741988.html↩↩↩↩